YZY Biopharma
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $50M
Overview
Clinical-stage biotech developing bispecific antibody therapeutics for oncology and immunology using proprietary T-cell engager technology.
OncologyImmunology
Technology Platform
Proprietary bispecific antibody engineering platform focused on T-cell engagers and immune modulators with optimized binding and pharmacokinetic properties.
Opportunities
Growing global market for bispecific antibodies exceeding $20 billion by 2030, with potential for novel target combinations in oncology and autoimmune diseases.
Risk Factors
Clinical failure risk for novel mechanisms, intense competition from established pharma companies, and regulatory challenges in global expansion beyond China.
Competitive Landscape
Competes with Roche, Amgen, and Regeneron in bispecific antibodies, with differentiation through novel target combinations and optimized molecular designs for improved safety profiles.